Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers. Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in ...
Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A U.S. Food and Drug Administration pooled analysis. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback